16 episodes

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerView Gastroenterology CME/CNE/CPE Video Podcast PVI, PeerView Institute for Medical Education

    • Science

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    • video
    Milind Javle, MD - Enhancing Standards of Care for Patients With Biliary Tract Cancers: A Graphical Guide to Integrating a New Lineup of Targeted Therapies Into Practice

    Milind Javle, MD - Enhancing Standards of Care for Patients With Biliary Tract Cancers: A Graphical Guide to Integrating a New Lineup of Targeted Therapies Into Practice

    Go online to PeerView.com/GZS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in gastrointestinal oncology provides an update on targeted therapies for patients with biliary tract cancers. Upon completion of this activity, participants should be better able to: Review the rationale of newly discovered targets, such as multikinase tumor pathways, NTRK gene fusions, and FGFR translocations, for biliary tract cancers, Appraise emerging efficacy and safety evidence on the use of novel targeted agents, including multikinase, TRK, and FGFR inhibitors, in patients with biliary tract cancers, Incorporate novel targeted agents safely and effectively into treatment plans for biliary tract cancers, including in the context of a clinical trial

    • 23 min
    • video
    Richard S. Finn, MD - The Expanding Playbook of Hepatocellular Carcinoma: Examining Scientific Data and Evidence With Your Multidisciplinary Team

    Richard S. Finn, MD - The Expanding Playbook of Hepatocellular Carcinoma: Examining Scientific Data and Evidence With Your Multidisciplinary Team

    Go online to PeerView.com/UHH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hepatocellular carcinoma (HCC) discuss how to effectively care for patients with HCC using multidisciplinary strategies in the context of an expanded and novel treatment arsenal. The faculty discusses pivotal clinical evidence of approved targeted and immune checkpoint inhibitor agents and how to effectively select and integrate therapies into individualized treatment plans for patients with HCC. Upon completion of this activity, participants will be able to: Appraise pivotal safety and efficacy data on approved targeted and immune checkpoint therapies for advanced HCC, Describe the significance of emerging data that continue to evolve the standards of care for patients with HCC, including biomarker-driven therapies, combination strategies using immunotherapy and targeted therapies, and novel therapeutic approaches for locoregional disease, Manage anticipated adverse events associated with targeted therapy and immunotherapy for patients with advanced HCC, Select optimal therapeutic options, including consideration of clinical trials, in the first and second lines of treatment for patients with advanced HCC, Incorporate multidisciplinary care approaches for the management of challenging patients with HCC, including those with locoregional disease who are candidates for early transition to systemic therapy or those with Child–Pugh B status, among others

    • 1 hr 17 min
    • video
    Amit Singal, MD, MS - MasterClass & Tumor Board⁠—Joining Forces in Hepatocellular Carcinoma: Enhancing Multidisciplinary Care in an Era of New Therapeutic Solutions

    Amit Singal, MD, MS - MasterClass & Tumor Board⁠—Joining Forces in Hepatocellular Carcinoma: Enhancing Multidisciplinary Care in an Era of New Therapeutic Solutions

    Go online to PeerView.com/GWD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView MasterClass and Tumor Board video activity, based on an educational session from The Liver Meeting® (American Association for the Study of Liver Diseases) in Boston, features a panel of hepatology, oncology, surgery, and interventional radiology experts, who provide their clinical perspectives on cutting-edge science that has validated, newly available systemic treatment options in HCC. Coupled with each MasterClass, the Tumor Board segments feature reflective case-centered discussions on the crucial role that hepatology clinicians serve across the HCC continuum of care. Upon completion of this activity, participants should be better able to: Evaluate the safety and efficacy data of multikinase and checkpoint inhibitors and antiangiogenic therapy indicated for advanced HCC, Summarize emerging clinical evidence on the use of novel systemic options in conjunction with or as an alternative to continued LRT for patients with intermediate HCC, Implement multidisciplinary team-based approaches to develop safe, personalized treatment algorithms that utilize novel components for patients with HCC

    • 1 hr 30 min
    • video
    Ghassan Abou-Alfa, MD, MBA - Composing Personalized HCC Treatment Strategies: Insights on Harmonizing Patient Care With a Multidisciplinary Ensemble

    Ghassan Abou-Alfa, MD, MBA - Composing Personalized HCC Treatment Strategies: Insights on Harmonizing Patient Care With a Multidisciplinary Ensemble

    Go online to PeerView.com/XKX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hepatocellular carcinoma (HCC) is an aggressive, complex disease and is a leading cause of cancer-related deaths worldwide. Research endeavors to mitigate HCC mortality have led to rapid advances, especially in the past two years. Today, clinicians specializing in HCC have various treatment options to select for their patients across the spectrum of the disease, and the therapeutic landscape continues to evolve with promising results from ongoing clinical trials investigating novel approaches. This PeerView MasterClass and Tumor Board on-demand educational activity, based on a symposium held adjunct to the 13th Annual Conference of the International Liver Cancer Association (ILCA 2019), features a panel of multidisciplinary HCC experts who review pivotal evidence on available TKI, antiangiogenic, and checkpoint inhibitor therapies and their optimal treatment sequencing strategies, as well as emerging data on novel combinations and innovative modalities for early- to advanced-stage disease. The experts weave the science into real-world case scenarios, helping to translate the data into practical experiences in the HCC clinic. Upon completion of this activity, participants should be better able to: Summarize recent safety and efficacy evidence of available targeted therapies, such as multikinase inhibitors and monoclonal antibodies, for HCC, Evaluate the significance of new data and ongoing clinical trials with checkpoint inhibitors as treatment options for HCC, Review the potential use of systemic treatments in novel multimodal strategies for intermediate HCC, Construct safe and effective treatment plans across multiple lines of therapy for patients with HCC based on multidisciplinary team–based strategies

    • 1 hr 15 min
    • video
    Matthew T. Ballo, MD, FACR - Readying the Modern Radiation Oncology Practice for Incorporation of a Fourth Modality in Cancer Treatment: Understanding the Science, Evidence & Clinical Application Across a Range of Solid Malignancies

    Matthew T. Ballo, MD, FACR - Readying the Modern Radiation Oncology Practice for Incorporation of a Fourth Modality in Cancer Treatment: Understanding the Science, Evidence & Clinical Application Across a Range of Solid Malignancies

    Go online to PeerView.com/APQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While much of cancer therapy development focuses on systemic drugs and the mitigation of associated adverse events, new avenues utilizing innovative multimodal solutions have demonstrated the benefit of efficacy with minimal toxicity in solid tumors. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies have emerged and entered into the management paradigms of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM) and are set to evolve the standards of care for patients with other solid tumors as well. In this activity, based on a recent live symposium held in Chicago, Illinois, radiation and medical oncology experts review cutting-edge advancements in cancer technology, such as TTFields, and offer insight and case discussions illustrating the appropriate integration of innovative solutions into cancer management. Moreover, the expert panel reviews multimodal strategies in GBM and examines the impact of novel treatment modalities available for MPM, as well as new approaches that are emerging for other tumors, including thoracic, pancreatic, liver, and ovarian cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for the use of novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Assess the latest safety and efficacy evidence on innovative strategies available for the therapeutic management of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Cite the latest evidence and ongoing clinical trials on novel treatments, including combining TTFields or radiotherapy with systemic therapy, in multiple tumor types, such as lung, pancreatic, liver, and ovarian cancers, across different treatment settings, Plan strategies to integrate novel technologies into the therapeutic management of patients with cancer, including through enrollment in clinical trials

    • 1 hr 19 min
    • video
    Sorayah Bourenane, MSN, RN, CNL / Marianne Davies, DNP, ACNP, AOCNP - Identification, Triage, and Management of Immune-Related Adverse Effects in Patients With Cancer Presenting to the Emergency Department: Practical Guidance for Emergency Nurses

    Sorayah Bourenane, MSN, RN, CNL / Marianne Davies, DNP, ACNP, AOCNP - Identification, Triage, and Management of Immune-Related Adverse Effects in Patients With Cancer Presenting to the Emergency Department: Practical Guidance for Emergency Nurses

    Go online to PeerView.com/AMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Treatment of cancer has been transformed by the new immune checkpoint inhibitor class of agents that have shown remarkable benefit in many different types of tumors, but they can also cause unusual immune-related adverse effects (irAEs) that can affect any organ system. Expanding use of these immunotherapies in oncology means that emergency medicine professionals can expect to encounter an increasing number of patients experiencing various irAEs in emergency departments. Timely recognition, accurate diagnosis, and effective management of irAEs can ensure that patients derive maximum benefit from these therapies, and emergency nurses have an important role to play in evaluating and triaging these patients. This CNE educational on-demand activity combines lessons on everything emergency nurses need to know about cancer immunotherapies and irAEs with case discussions and practical guidance for keeping patients with cancer safe in the era of immuno-oncology. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-related adverse effects (irAEs), Characterize the presenting symptoms of the spectrum of irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by emergency nurses and other professionals in the emergency department (ED), Outline the general and organ/site-specific recommendations for the recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED, Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology specialists

    • 47 min

Top Podcasts In Science

Listeners Also Subscribed To